Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1822 1
1864 1
1883 1
1885 1
1909 1
1917 1
1920 1
1927 1
1937 1
1943 2
1945 25
1946 30
1947 227
1948 304
1949 274
1950 620
1951 705
1952 868
1953 822
1954 853
1955 822
1956 853
1957 846
1958 723
1959 254
1960 5
1961 4
1962 4
1963 642
1964 1011
1965 848
1966 832
1967 928
1968 983
1969 701
1970 629
1971 526
1972 369
1973 312
1974 340
1975 446
1976 424
1977 432
1978 505
1979 498
1980 558
1981 582
1982 677
1983 821
1984 1108
1985 1501
1986 1856
1987 2558
1988 3973
1989 4669
1990 5195
1991 5649
1992 6182
1993 6966
1994 7593
1995 8072
1996 8662
1997 9201
1998 9792
1999 10556
2000 11835
2001 12473
2002 13374
2003 14443
2004 15834
2005 17537
2006 18452
2007 19641
2008 20409
2009 21257
2010 23133
2011 24828
2012 26684
2013 28067
2014 31351
2015 34558
2016 36223
2017 37995
2018 40016
2019 41657
2020 48207
2021 52136
2022 50493
2023 47667
2024 49575
2025 50620
2026 293

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

814,958 results

Results by year

Filters applied: . Clear all
Page 1
Showing results for obi or il
Search for Obilor IL instead (2 results)
Venetoclax-obinutuzumab for previously untreated chronic lymphocytic leukemia: 6-year results of the randomized phase 3 CLL14 study.
Al-Sawaf O, Robrecht S, Zhang C, Olivieri S, Chang YM, Fink AM, Tausch E, Schneider C, Ritgen M, Kreuzer KA, Sivchev L, Niemann CU, Schwarer A, Loscertales J, Weinkove R, Strumberg D, Kilfoyle A, Manzoor BS, Jawaid D, Emechebe N, Devine J, Boyer M, Runkel ED, Eichhorst B, Stilgenbauer S, Jiang Y, Hallek M, Fischer K. Al-Sawaf O, et al. Blood. 2024 Oct 31;144(18):1924-1935. doi: 10.1182/blood.2024024631. Blood. 2024. PMID: 39082668 Free PMC article. Clinical Trial.
The 6-year OS rate was 78.7% in the Ven-Obi and 69.2% in the Clb-Obi arm (HR, 0.69; 95% CI, 0.48-1.01; P = .052). A significantly longer TUDD in global health status/QoL was observed in the Ven-Obi than in the Clb-Obi arm (median, 82.1 vs 65.1 months; …
The 6-year OS rate was 78.7% in the Ven-Obi and 69.2% in the Clb-Obi arm (HR, 0.69; 95% CI, 0.48-1.01; P = .052). A significan …
Occult Hepatitis B Virus Infection: An Update.
Saitta C, Pollicino T, Raimondo G. Saitta C, et al. Viruses. 2022 Jul 8;14(7):1504. doi: 10.3390/v14071504. Viruses. 2022. PMID: 35891484 Free PMC article. Review.
Occult hepatitis B virus (HBV) infection (OBI) refers to a condition in which replication-competent viral DNA is present in the liver (with detectable or undetectable HBV DNA in the serum) of individuals testing negative for the HBV surface antigen (HBsAg). ...Many advance …
Occult hepatitis B virus (HBV) infection (OBI) refers to a condition in which replication-competent viral DNA is present in the liver …
Effects of different B-cell-depleting strategies on the lymphatic tissue.
Tur C, Eckstein M, Bucci L, Auth J, Bergmann C, Rauber S, Hagen M, Nöthling DM, Böltz S, Wirsching A, Tascilar K, Fagni F, Corte G, Rius Rigau A, Qin Y, Garantziotis P, Taubmann J, Wacker J, Ramming A, D Agostino MA, Rauch S, Hartmann A, Müller F, Mackensen A, Grieshaber-Bouyer R, Schett G, Bozec A, Raimondo MG. Tur C, et al. Ann Rheum Dis. 2025 Jul 11:S0003-4967(25)04174-3. doi: 10.1016/j.ard.2025.06.2120. Online ahead of print. Ann Rheum Dis. 2025. PMID: 40651933 Free article.
RESULTS: Baseline and follow-up lymph node biopsies from 24 patients with AID (OBI, 4; BLI, 4; RTX, 4; CD19-CAR T cells, 12) were analysed. B cell depletion was confirmed in all CD19-CAR T cell-treated patients but only in 1 (OBI) out of 12 protein-based B cell-trea …
RESULTS: Baseline and follow-up lymph node biopsies from 24 patients with AID (OBI, 4; BLI, 4; RTX, 4; CD19-CAR T cells, 12) were ana …
Transcriptomic profiles and 5-year results from the randomized CLL14 study of venetoclax plus obinutuzumab versus chlorambucil plus obinutuzumab in chronic lymphocytic leukemia.
Al-Sawaf O, Zhang C, Jin HY, Robrecht S, Choi Y, Balasubramanian S, Kotak A, Chang YM, Fink AM, Tausch E, Schneider C, Ritgen M, Kreuzer KA, Chyla B, Paulson JN, Pallasch CP, Frenzel LP, Peifer M, Eichhorst B, Stilgenbauer S, Jiang Y, Hallek M, Fischer K. Al-Sawaf O, et al. Nat Commun. 2023 Apr 18;14(1):2147. doi: 10.1038/s41467-023-37648-w. Nat Commun. 2023. PMID: 37072421 Free PMC article. Clinical Trial.
In this open-label parallel-group phase-3 study, 432 patients with previously untreated CLL were randomized (1:1) to receive either 1-year venetoclax-obinutuzumab (Ven-Obi, 216 patients) or chlorambucil-Obi (Clb-Obi, 216 patients) therapy (NCT02242942). ...Af …
In this open-label parallel-group phase-3 study, 432 patients with previously untreated CLL were randomized (1:1) to receive either 1-year v …
Work-Life Balance.
Obi GM. Obi GM. Plast Aesthet Nurs (Phila). 2023 Jan-Mar 01;43(1):3. doi: 10.1097/PSN.0000000000000477. Plast Aesthet Nurs (Phila). 2023. PMID: 36583577 No abstract available.
OBI-992, a Novel TROP2-Targeted Antibody-Drug Conjugate, Demonstrates Antitumor Activity in Multiple Cancer Models.
Li WF, Chiang MF, Weng HC, Yang JJ, Wu HS, Wu SY, Chen YJ, Lu CH, Tu JS, Hsu RY, Shia CS, Huang TY, Lai MT. Li WF, et al. Mol Cancer Ther. 2025 Feb 4;24(2):163-175. doi: 10.1158/1535-7163.MCT-24-0588. Mol Cancer Ther. 2025. PMID: 39786401 Free PMC article.
In a large-tumor model, longer survival times were observed in OBI-992-treated mice compared with Dato-DXd-treated mice. OBI-992 treatment induced marked bystander killing of TROP2-negative cells in the presence of nearby TROP2-positive cells in both in vitro and in …
In a large-tumor model, longer survival times were observed in OBI-992-treated mice compared with Dato-DXd-treated mice. OBI-9 …
On-Treatment Verification Imaging.
Sethi A, Mihailidis DN. Sethi A, et al. Med Phys. 2020 Dec 31. doi: 10.1002/mp.14693. Online ahead of print. Med Phys. 2020. PMID: 33382461 Review.
The integration of on-board imaging (OBI) with linear accelerators paved the way for Image Guided Radiation Therapy (IGRT) as it is practiced today in the clinic. ...
The integration of on-board imaging (OBI) with linear accelerators paved the way for Image Guided Radiation Therapy (IGRT) as it is p …
Occult HBV infection.
Raimondo G, Caccamo G, Filomia R, Pollicino T. Raimondo G, et al. Semin Immunopathol. 2013 Jan;35(1):39-52. doi: 10.1007/s00281-012-0327-7. Epub 2012 Jul 26. Semin Immunopathol. 2013. PMID: 22829332 Free PMC article. Review.
The development of an immunosuppressive status (mainly by immunotherapy or chemotherapy) may induce OBI reactivation and development of acute and often severe hepatitis. Finally, evidence suggests that OBI can favor the progression of liver fibrosis, in particular i …
The development of an immunosuppressive status (mainly by immunotherapy or chemotherapy) may induce OBI reactivation and development …
Isatuximab Subcutaneous by On-Body Injector Versus Isatuximab Intravenous Plus Pomalidomide and Dexamethasone in Relapsed/Refractory Multiple Myeloma: Phase III IRAKLIA Study.
Ailawadhi S, Špička I, Spencer A, Lu J, Oriol A, Ling S, Schjesvold F, Berkovits A, Hus M, Li C, Dimopoulos MA, Rajnics P, Beşışık SK, Hungria V, Custidiano MDR, Parmar G, Leleu X, Li F, Cerchione C, Gomez C, Ishida T, Mateos MV, Buck TT, LeBlanc R, Minařík J, Goldschmidt H, Zhang R, Sémiond D, Suzan F, Stefanova-Urena M, Koch V, Moreau P. Ailawadhi S, et al. J Clin Oncol. 2025 Aug;43(22):2527-2537. doi: 10.1200/JCO-25-00744. Epub 2025 Jun 3. J Clin Oncol. 2025. PMID: 40459178 Clinical Trial.
CONCLUSION: IRAKLIA demonstrated efficacy and pharmacokinetic noninferiority between Isa OBI and IV. No unexpected safety signal was observed, with excellent local tolerability of Isa OBI. Efficacy and safety were comparable with Isa IV in ICARIA-MM, except the lowe …
CONCLUSION: IRAKLIA demonstrated efficacy and pharmacokinetic noninferiority between Isa OBI and IV. No unexpected safety signal was …
An overview of occult hepatitis B infection (OBI) with emphasis on HBV vaccination.
Delghandi S, Raoufinia R, Shahtahmasbi S, Meshkat Z, Gouklani H, Gholoobi A. Delghandi S, et al. Heliyon. 2024 Aug 28;10(17):e37097. doi: 10.1016/j.heliyon.2024.e37097. eCollection 2024 Sep 15. Heliyon. 2024. PMID: 39281486 Free PMC article. Review.
This study aims to offer a more comprehensive understanding of the implications of widespread HBV vaccination initiatives on OBI while tackling the primary limitations associated with current vaccine formulations. METHODS: The exploration was conducted on PubMed, Scopus, a …
This study aims to offer a more comprehensive understanding of the implications of widespread HBV vaccination initiatives on OBI whil …
814,958 results
You have reached the last available page of results. Please see the User Guide for more information.